Gramine suppresses triple-negative breast cancer by inducing ferroptosis via CUL3-mediated ubiquitination of MTDH

Current Molecular Pharmacology · Published 2026-01-01 · DOI 10.1016/j.cmp.2026.03.001

Free full text

Authors being retrieved — see the publisher record. https://doi.org/10.1016/j.cmp.2026.03.001

Abstract

PubPorta does not have an abstract for this article yet.

Read the article at the publisher →

Publication details

Year

2026

Related articles

• ITPKB suppresses ER calcium release to promote CXCL9 expression and enhance immunotherapy sensitivity in triple-negative breast cancer · Drug Resistance Updates · 2026 · Cites or is cited by this article
• Targeting fPRDM16 to restore collagen phagocytosis: A mechanism to counteract the persistent fibrosis in aging lungs · Current Molecular Pharmacology · 2026 · Same journal
• Chrysin: A Potential Antiandrogen Ligand to Mutated Androgen Receptors in Prostate Cancer · Current Molecular Pharmacology · 2025 · Same journal
• Protective Effect of Platycodin D on Allergic Rhinitis in Mice through DPP4/JAK2/STAT3 Pathway Inhibition · Current Molecular Pharmacology · 2025 · Same journal
• Neuroprotective Potential of Tanshinone-IIA in Mitigating Propionic Acidinduced Experimental Autism-like Behavioral and Neurochemical Alterations: Insights into c-JNK and p38MAPK Pathways · Current Molecular Pharmacology · 2024 · Same journal
• Regulatory Mechanisms of STAT3 in GBM and its Impact on TMZ Resistance · Current Molecular Pharmacology · 2025 · Same journal
• Optimization of bioinformatics-designed thiazolide derivatives as SARS-CoV-2 nucleocapsid protein inhibitors · Current Molecular Pharmacology · 2026 · Same journal
• Doxazosin Attenuates Development of Testosterone Propionate-induced Prostate Growth by regulating TGF-β/Smad Signaling Pathway, Prostate-specific Antigen Expression and Reversing Epithelial-Mesenchymal Transition in Mice and Stroma Cells · Current Molecular Pharmacology · 2025 · Same journal
• Intra-tumor DKK1 and CALML5 heterogeneity as a novel biomarker for prognosis and immunotherapy response in head and neck squamous cell carcinoma · Current Molecular Pharmacology · 2025 · Same journal
• IGFBP1 is a potential monitoring biomarker of disease activity in elderly patients with inflammatory bowel disease · Current Molecular Pharmacology · 2026 · Same journal